Antipsychotic for dementia-related agitation, contaminated water at Camp Lejeune associated with elevated risk for Parkinson's, gene variant confers resilience against autosomal dominant Alzheimer's.
In this week's podcast, Neurology Today's editor-in-chief discusses the FDA approval of an antipsychotic for agitation in dementia, elevated risk for Parkinson's in Camp Lejeune Marines exposed to contaminated water, a gene variant delays the onset of symptoms in man with autosomal dominant Alzheimer's. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
15 Kesä 20235min
OnabotulinumtoxinA for pregnant women with migraine, adderrall shortage, AI for epilepsy
In this week's podcast, Neurology Today's editor-in-chief discusses a study on the safety of omnabotuliumtoxinA on pregnant women with migraine, the impact of the Adderall shortage on patients with ADHD and narcolepsy, and the state of AI for epilepsy. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
1 Kesä 20235min
Assay detects Parkinson's before symptom onset; life stressors in pregnant women with epilepsy; role of inflammation in NORSE
In this week's podcast, Neurology Today's editor-in-chief discusses a new study reporting a gene assay detected Parkinson's before symptoms onset, life stressors greatly impact women with epilepsy during pregnancy; the role of inflammation in new-onset refractory status epilepticus. This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
18 Touko 20235min
Anticoagulants for patients with dementia and Afib, tau levels in women taking hormone replace therapy, neurohumanities programs for neurology residents.
In this week's podcast, Neurology Today's editor-in-chief discusses a new study finding anticoagulants are safe for patients with atrial fibrillation and dementia, women on hormone replacement therapy had higher tau levels, and neurology residents are participants in humanities programs to foster wellness.
4 Touko 20235min
Fertility treatments for women with MS, stroke systems of care, ravalizumab for NMOSD
In this week's podcast, Neurology Today's editor-in-chief discusses a new study finding fertility treatments did not lead to MS relapses for women, a AHA consensus statement that finds stroke systems need improvement, and ravalizumab at less frequent doses was effective for neuromyelitis optica spectrum disorder.
20 Huhti 20235min
Intranasal CGRP for migraine, ultrasound ablation for Parkinson's disease, novel therapeutic pathway for Duchenne muscular atrophy.
In this week's podcast, Neurology Today's editor-in-chief discusses the newly approved zavegepant for migraine, the potential/caveats of ultrasound ablation for Parkinson's disease, the transational potential of a new therapeutic target for Duchenne muscular atrophy.
6 Huhti 20236min
Antipsychotics and dementia risk; biomarkers for lecanemab eligibility; trial of difelikefalin for neurogenic itch in notaliga paresthetica.
In this week's podcast, Neurology Today's editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer's, and a novel approach for managing uncomfortable neuropathic symptoms.
16 Maalis 20236min
Pregnancy-associated stroke outcomes; a robotic device for shoulder movement in ALS; non-invasive neurostimulation for refractory seizures.
In this week's podcast, Neurology Today's editor-in-chief discusses long-term adverse outcomes from pregnancy-associated stroke, a robotic device to assist shoulder movement in ALS, and the promise of neurostimulation for refractory seizures in the ICU.
2 Maalis 20235min
